These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 16369533)
1. Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Takahashi C; Contreras B; Iwanaga T; Takegami Y; Bakker A; Bronson RT; Noda M; Loda M; Hunt JL; Ewen ME Nat Genet; 2006 Jan; 38(1):118-23. PubMed ID: 16369533 [TBL] [Abstract][Full Text] [Related]
2. E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Ziebold U; Lee EY; Bronson RT; Lees JA Mol Cell Biol; 2003 Sep; 23(18):6542-52. PubMed ID: 12944480 [TBL] [Abstract][Full Text] [Related]
3. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Komminoth P Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627 [TBL] [Abstract][Full Text] [Related]
4. Genetic interaction between Rb and N-ras: differentiation control and metastasis. Takahashi C; Ewen ME Cancer Res; 2006 Oct; 66(19):9345-8. PubMed ID: 17018584 [TBL] [Abstract][Full Text] [Related]
5. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231 [TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumors of the thyroid gland. Baloch ZW; LiVolsi VA Am J Clin Pathol; 2001 Jun; 115 Suppl():S56-67. PubMed ID: 11993691 [TBL] [Abstract][Full Text] [Related]
7. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Harvey M; Vogel H; Lee EY; Bradley A; Donehower LA Cancer Res; 1995 Mar; 55(5):1146-51. PubMed ID: 7867001 [TBL] [Abstract][Full Text] [Related]
15. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. Cerrato A; De Falco V; Santoro M J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg. Rendl G; Rodrigues M; Schweighofer-Zwink G; Hutter J; Hittmair A; Zellinger B; Hauser-Kronberger C; Pirich C Wien Klin Wochenschr; 2017 Aug; 129(15-16):540-544. PubMed ID: 28493027 [TBL] [Abstract][Full Text] [Related]
17. Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. Lázaro S; Pérez-Crespo M; Enguita AB; Hernández P; Martínez-Palacio J; Oteo M; Sage J; Paramio JM; Santos M Oncotarget; 2017 Jan; 8(3):4373-4386. PubMed ID: 27966456 [TBL] [Abstract][Full Text] [Related]
18. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer. Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368 [TBL] [Abstract][Full Text] [Related]
19. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors. Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms. Papadimitriou K; Yiagnisis M; Tolis G; Spandidos DA Anticancer Res; 1988; 8(6):1223-7. PubMed ID: 3064713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]